IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
IMUNON (NASDAQ: IMNN) has scheduled its Third Quarter 2024 Financial Results conference call for Thursday, November 7, 2024, at 11:00 a.m. ET. The company will discuss Q3 2024 financial performance and provide updates on two key programs: IMNN-001, a DNA-based IL-12 immunotherapy for first-line ovarian cancer treatment, and PlaCCine, their DNA plasmid technology for next-generation vaccine development. The call will be accessible via phone and webcast, with replay available until November 21, 2024.
IMUNON (NASDAQ: IMNN) ha programmato una conference call per i Risultati Finanziari del Terzo Trimestre 2024 per giovedì 7 novembre 2024, alle 11:00 a.m. ET. L'azienda discuterà le performance finanziarie del Q3 2024 e fornirà aggiornamenti su due programmi chiave: IMNN-001, una terapia immunitaria IL-12 basata su DNA per il trattamento di prima linea del cancro ovarico, e PlaCCine, la loro tecnologia plasmidica DNA per lo sviluppo di vaccini di nuova generazione. La chiamata sarà accessibile tramite telefono e webcast, con riproduzione disponibile fino al 21 novembre 2024.
IMUNON (NASDAQ: IMNN) ha programado una conference call para los Resultados Financieros del Tercer Trimestre 2024 el jueves 7 de noviembre de 2024, a las 11:00 a.m. ET. La compañía discutirá el desempeño financiero del Q3 2024 y proporcionará actualizaciones sobre dos programas clave: IMNN-001, una inmunoterapia IL-12 basada en ADN para el tratamiento de cáncer de ovario de primera línea, y PlaCCine, su tecnología de plásmido de ADN para el desarrollo de vacunas de próxima generación. La llamada será accesible a través de teléfono y webcast, con reproducción disponible hasta el 21 de noviembre de 2024.
IMUNON (NASDAQ: IMNN)은 2024년 11월 7일 목요일 오전 11시(ET)에 2024년 3분기 재무 결과에 대한 콘퍼런스 콜을 예정했습니다. 회사는 2024년 3분기 재무 성과를 논의하고 두 가지 주요 프로그램에 대한 업데이트를 제공할 것입니다: IMNN-001, 1차 난소암 치료를 위한 DNA 기반 IL-12 면역 요법, 그리고 PlaCCine, 차세대 백신 개발을 위한 그들의 DNA 플라스미드 기술입니다. 콜은 전화 및 웹캐스트를 통해 접근 가능하며, 2024년 11월 21일까지 다시 들으실 수 있습니다.
IMUNON (NASDAQ: IMNN) a programmé une conférence téléphonique concernant ses Résultats Financiers du Troisième Trimestre 2024 pour le jeudi 7 novembre 2024, à 11h00 ET. L'entreprise discutera de la performance financière du T3 2024 et fournira des mises à jour sur deux programmes clés : IMNN-001, une immunothérapie IL-12 à base d'ADN pour le traitement de première ligne du cancer de l'ovaire, et PlaCCine, leur technologie de plasmide ADN pour le développement de vaccins de nouvelle génération. L'appel sera accessible par téléphone et webcast, avec une rediffusion disponible jusqu'au 21 novembre 2024.
IMUNON (NASDAQ: IMNN) hat eine Telefonkonferenz zu den Finanzergebnissen des dritten Quartals 2024 für Donnerstag, den 7. November 2024, um 11:00 Uhr ET angesetzt. Das Unternehmen wird die finanzielle Leistung des Q3 2024 besprechen und Updates zu zwei Schlüsselprogrammen geben: IMNN-001, eine DNA-basierte IL-12 Immuntherapie zur Erstlinienbehandlung von Eierstockkrebs, und PlaCCine, ihre DNA-Plasmidtechnologie zur Entwicklung von Impfstoffen der nächsten Generation. Der Anruf ist per Telefon und Webcast zugänglich, mit einer Wiederholungsmöglichkeit bis zum 21. November 2024.
- None.
- None.
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.
To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2024 Earnings Call. A live webcast of the call will also be available here.
The call will be archived for replay until November 21, 2024, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 6852891. An audio replay of the call will also be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing for commencement of a Phase 3 trial of IMNN-001, the timing and outcome of the Company’s End-of-Phase 2 meeting with the FDA, the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
IMUNON | LHA Investor Relations |
David Gaiero | Kim Sutton Golodetz |
978-376-6352 | 212-838-3777 |
dgaiero@imunon.com | kgolodetz@lhai.com |
# # #
FAQ
When is IMUNON (IMNN) releasing its Q3 2024 earnings?
How can investors access IMUNON's (IMNN) Q3 2024 earnings call?